神经退行性疾□□病市场：按适应症类型、药物类型、地区划分——规模、份额、展望、机会分析，2023-2030 年

神经退行性疾□□病是一种中枢神经系统细胞停止工作或死亡的疾病。 神经退行性疾□□病是由神经细胞结构或功能在称为神经变性的过程中逐渐丧失引起的。 阿尔茨海默病和帕金森病是最常见的神经退行性疾□□病。 神经退行性疾□□病通常会随着时间的推移而恶化，并且无法治愈。

市场动态：

神经退行性疾□□病患病率上升，人口老龄化加剧，对安全有效疗法的需求不断增长，公众对神经退行性疾□□病和可用疗法的认识不断提高，强大的产品管线是预计将推动全球神经退行性疾□□病市场增长的主要因素在预测期间。

例如，2022 年 10 月，Cyclo Therapeutics 将开始一项名为 Trappsol Cyclo 的研究药物的 2b 期试验，该药物用于治疗早期阿尔茨海默病，目标是减少淀粉样蛋白和 tau 蛋白。

此外，2022 年 8 月，Amneal Pharmaceuticals 向美国食品药品监督管理局 (FDA) 提交了 IPX203 的新药申请，IPX203 是一种用于治疗帕金森病的卡比多巴/左旋多巴缓释胶囊的新型口服製剂。

这项研究的主要特点

• 本报告对全球神经退行性疾□□病市场进行了深入分析，提供了以 2022 年为基准年的预测期（2023-2030 年）的市场规模和復合年增长率 (CAGR%) 增长情况。
• 它还阐明了各个细分市场的潜在创收机会，并描述了该市场具有吸引力的投资建议矩阵。
• 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 它根据以下参数介绍了全球神经退行性疾□□病市场的主要参与者，包括公司亮点、产品组合、主要亮点、财务业绩和战略。
• 参与这项研究的主要公司包括 Amneal Pharmaceuticals Inc.、Boehringer Ingelheim International Gmbh、F. Hoffmann-La Roche、Abbvie Inc.、Merck & Co. Inc.。
• 这份报告中的见解可以让营销人员和企业高管就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。奖。
• 《全球神经退行性疾□□病市场》报告面向行业内的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球神经退行性疾□□病市场的各种战略矩阵来促进决策制定。

内容

第一章调查的目的和前提

• 调查目的
• 先决条件
• 缩写说明

第二章市场范围

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按适应症类型分类
  • 按药物类型划分的市场概况
  • 市场概况：按地区
• 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 神经退行性疾□□病患病率上升
  • 严格的监管准则
  • 扩大对新药的需求
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/批准
• 害虫分析
• 对 PORTER 的分析
• 合併/收购场景

第 4 章全球神经退行性疾□□病市场 - 冠状病毒 (COVID-19) 大流行的影响

• COVID-19 流行病学
• 供应方和需求方分析
• 经济影响

第 5 章全球神经退行性疾□□病市场：按适应症类型，2017-2030

• 帕金森病
• 阿尔茨海默氏痴呆症
• 多发性硬化症
• 亨廷顿舞蹈症
• 其他显示类型

第 6 章全球神经退行性疾□□病市场，按药物类型，2017-2030

• N-甲基-D-天冬氨酸受体拮抗剂
• 胆碱酯□抑製剂
• 多巴胺激动剂
• 免疫调节剂
• 其他药物类型

第 7 章：2017-2030 年按地区分列的全球神经退行性疾□□病市场

• 北美
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲
• 世界其他地区

第八章竞争格局

• Abbvie Inc.
• Amneal Pharmaceuticals Inc.
• Boehringer Ingelheim International Gmbh
• F. Hoffmann-La Roche
• Merck & Co. Inc.

第 9 章

• 调查方法
• 关于出版商

Neurodegenerative disease is a type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in a process known as neurodegeneration. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. Neurodegenerative disorders usually get worse over time and have no cure.

Market Dynamics:

Rise in prevalence of neurodegenerative diseases, growing geriatric population, rise in demand for safe and effective therapeutics, increasing public awareness about neurodegenerative disease and available therapeutics, and strong product pipeline are major factors expected to propel growth of the global neurodegenerative disease market over the forecast period.

For instance, in October 2022, Cyclo Therapeutics announced the launch of a Phase 2b study for its investigational drug, named Trappsol Cyclo, which targets the reduction of amyloid beta and tau to treat early Alzheimer's disease.

Moreover, in August 2022, Amneal Pharmaceuticals submitted a New Drug Application to the Food & Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.

Key Features of the Study:

• This report provides in-depth analysis of the global neurodegenerative disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global neurodegenerative disease market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, Abbvie Inc., and Merck & Co. Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global neurodegenerative disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurodegenerative disease market.

Detailed Segmentation:

• Global Neurodegenerative Disease Market, By Indication Type:
  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Huntington Disease
  • Other Indication Types
• Global Neurodegenerative Disease Market, By Drug Type:
  • N-methyl-D-aspartate Receptor antagonists
  • Cholinesterase Inhibitors
  • Dopamine Agonists
  • Immunomodulatory Drugs
  • Other Drug Types
• Global Neurodegenerative Disease Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Abbvie Inc.
  • Amneal Pharmaceuticals Inc.
  • Boehringer Ingelheim International Gmbh
  • Hoffmann-La Roche
  • Merck & Co. Inc.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Indication Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in prevalence of neurodegenerative diseases
  • Stringent regulatory guidelines
  • Increase in demand for novel therapeutics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Neurodegenerative Disease Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Neurodegenerative Disease Market, By Indication Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Parkinson's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Alzheimer's Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Multiple Sclerosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Huntington Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Other Indication Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Neurodegenerative Disease Market, By Drug Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• N-methyl-D-aspartate Receptor Antagonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Dopamine Agonists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Immunomodulatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Other Drug Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Neurodegenerative Disease Market, By Geography, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)

8. Competitive Landscape

• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim International Gmbh
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us